Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adipic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | F13A1 | P00488 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adipic Acid SCHEMBL29427201 | 1.00 | LMNA (0.50) | LMNANFKB1TSHRPMP22SLC22A6 | |
| Sebacic Acid SCHEMBL28228671 | 0.98 | TSHR (0.52) | LMNANFKB1TSHRPMP22SLC22A6 | |
| Azelaic Acid SCHEMBL28918234 | 0.98 | TSHR (0.52) | LMNANFKB1TSHRPMP22SLC22A6 | |
| Octanedioate SCHEMBL6037661 | 0.98 | TSHR (0.52) | LMNANFKB1TSHRPMP22SLC22A6 | |
| Octanedioate SCHEMBL1394807 | 0.98 | TSHR (0.52) | LMNANFKB1TSHRPMP22SLC22A6 | |
| Glutarate SCHEMBL9485824 | 0.95 | SLC22A6 (0.50) | LMNANFKB1TSHRPMP22SLC22A6 | |
| Glutarate SCHEMBL28487046 | 0.95 | SLC22A6 (0.50) | LMNANFKB1TSHRPMP22SLC22A6 | |
| Sebacic Acid SCHEMBL29286911 | 0.92 | GPR84 (0.50) | LMNANFKB1TSHRPMP22SLC22A6 | |
| Succinic Acid SCHEMBL28916613 | 0.91 | LMNA (0.45) | LMNANFKB1TSHRPMP22SLC22A6 | |
| Succinic Acid SCHEMBL722926 | 0.91 | LMNA (0.45) | LMNANFKB1TSHRPMP22SLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857693-B2 | Medical sealant glue capable of promoting wound healing and preparation method thereof | SHANDONG BRANDEN MEDICAL DEVICE CO., LTD (CN) | 2024-01-02 | — | — | US | claimed |
| CN-115721775-B | Composite modified biological hydrogel dressing and preparation process thereof | 海南苏生生物科技有限公司 | 2023-09-29 | — | — | CN | claimed |
| US-20230137914-A1 | nOMV-ANTIGEN CONJUGATED COMPOUNDS AND USE THEREOF | GLAXOSMITHKLINE BIOLOGICALS, S.A. (BE) | 2023-05-04 | — | — | US | claimed |
| US-20220008529-A1 | MULTI-FUNCTIONALIZED noMV CONJUGATES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-01-13 | — | — | US | claimed |
| EP-3799883-A1 | NOMV-ANTIGEN CONJUGATED COMPOUNDS AND USE THEREOF | GlaxoSmithKline Biologicals S.A. (BE) | 2021-04-07 | — | — | EP | claimed |
| EP-3544637-B1 | NATIVE OMV-ANTIGEN CONJUGATES AND USE THEREOF | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2020-11-11 | — | — | EP | claimed |
| EP-3664837-A1 | MULTI-FUNCTIONALIZED nOMV CONJUGATES | GlaxoSmithKline Biologicals S.A. (BE) | 2020-06-17 | — | — | EP | claimed |
| US-10683370-B2 | Methods for making saccharide-protein glycoconjugates | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2020-06-16 | — | — | US | claimed |
| EP-3544637-A1 | nOMV-ANTIGEN CONJUGATES AND USE THEREOF | GlaxoSmithKline Biologicals S.A. (BE) | 2019-10-02 | — | — | EP | claimed |
| CN-110248681-A | nOMV-antigen conjugates and uses thereof | 葛兰素史密丝克莱恩生物有限公司 | 2019-09-17 | — | — | CN | claimed |
| US-20170246285-A1 | Conjugation of Streptococcal Capsular Saccharides | NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) | 2017-08-31 | — | — | US | claimed |
| US-9358284-B2 | Methods for making saccharide-protein glycoconjugates | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2016-06-07 | — | — | US | claimed |
| CN-103349780-B | The coupling of streptococcus capsular saccharides | NOVARTIS VACCINES & DIAGNOSTIC (IT) | 2016-05-04 | — | — | CN | claimed |
| US-20150231231-A1 | Conjugation of Streptococcal Capsular Saccharides | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2015-08-20 | — | — | US | claimed |
| US-20140329998-A1 | METHODS FOR MAKING SACCHARIDE-PROTEIN GLYCOCONJUGATES | NOVARTIS AG (CH) | 2014-11-06 | — | — | US | claimed |
| EP-2755683-A2 | METHODS FOR MAKING SACCHARIDE-PROTEIN GLYCOCONJUGATES | Novartis AG (CH) | 2014-07-23 | — | — | EP | claimed |
| WO-2013038375-A2 | METHODS FOR MAKING SACCHARIDE-PROTEIN GLYCOCONJUGATES | NOVARTIS AG (CH) | 2013-03-21 | — | — | WO | claimed |
| US-20090043077-A1 | Conjugation of streptococcal capsular saccharides | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2009-02-12 | — | — | US | claimed |
| EP-1846038-A2 | CONJUGATION OF STREPTOCOCCAL CAPSULAR SACCHARIDES | Novartis Vaccines and Diagnostics S.r.l. (IT) | 2007-10-24 | — | — | EP | claimed |
| WO-2006082530-A2 | CONJUGATION OF STREPTOCOCCAL CAPSULAR SACCHARIDES TO CARRIER PROTEINS | NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) | 2006-08-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230137914-A1 | nOMV-ANTIGEN CONJUGATED COMPOUNDS AND USE THEREOF | VAPB, CD14, CHMP4B | LMNA 3099/4885NFKB1 1723/4885TSHR 4408/4885 |
| US-20150231231-A1 | Conjugation of Streptococcal Capsular Saccharides | FUT5, CSGALNACT1, B3GNT2 | LMNA 2743/4885NFKB1 4411/4885TSHR 1636/4885 |
| US-20140329998-A1 | METHODS FOR MAKING SACCHARIDE-PROTEIN GLYCOCONJUGATES | ENGASE, SI, STT3A | LMNA 2930/4885NFKB1 3474/4885TSHR 3715/4885 |
| US-20170246285-A1 | Conjugation of Streptococcal Capsular Saccharides | FUT5, CSGALNACT1, B3GNT2 | LMNA 2743/4885NFKB1 4411/4885TSHR 1636/4885 |
| US-20220008529-A1 | MULTI-FUNCTIONALIZED noMV CONJUGATES | CD14, CHMP4B, VAPB | LMNA 3666/4885NFKB1 1864/4885TSHR 4021/4885 |
| US-10683370-B2 | Methods for making saccharide-protein glycoconjugates | SI, ENGASE, STT3A | LMNA 2947/4885NFKB1 3292/4885TSHR 3854/4885 |
| US-20090043077-A1 | Conjugation of streptococcal capsular saccharides | CSGALNACT1, FUT5, GNE | LMNA 3008/4885NFKB1 4677/4885TSHR 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.